U.S. Markets closed
  • S&P 500

    4,432.99
    -40.76 (-0.91%)
     
  • Dow 30

    34,584.88
    -166.44 (-0.48%)
     
  • Nasdaq

    15,043.97
    -137.96 (-0.91%)
     
  • Russell 2000

    2,236.87
    +3.96 (+0.18%)
     
  • Crude Oil

    71.96
    -0.65 (-0.90%)
     
  • Gold

    1,753.90
    -2.80 (-0.16%)
     
  • Silver

    22.42
    -0.33 (-1.44%)
     
  • EUR/USD

    1.1732
    -0.0040 (-0.3402%)
     
  • 10-Yr Bond

    1.3700
    +0.0390 (+2.93%)
     
  • Vix

    20.81
    +2.12 (+11.34%)
     
  • GBP/USD

    1.3737
    -0.0059 (-0.4286%)
     
  • USD/JPY

    109.8950
    +0.1770 (+0.1613%)
     
  • BTC-USD

    48,649.69
    +1,205.76 (+2.54%)
     
  • CMC Crypto 200

    1,193.48
    -32.05 (-2.62%)
     
  • FTSE 100

    6,963.64
    -63.84 (-0.91%)
     
  • Nikkei 225

    30,500.05
    +176.71 (+0.58%)
     

CureVac Slumps After Confirming COVID Vaccine Candidate Only 48% Effective

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

By Dhirendra Tripathi

Investing.com – CureVac (NASDAQ:CVAC) stock plunged 13% in Thursday’s premarket trading after the German drugmaker said final test data showed its experimental vaccine against COVID-19 was only 48% effective in preventing the disease.

The German biotech had already said two weeks ago that initial lab results suggested its COVID-19 vaccine, known as CVnCoV, was only 47% effective, adding that new variants of the virus had proved a headwind.

Most vaccines in the market, including those by Pfizer (NYSE:PFE)-BioNTech (NASDAQ:BNTX) and Moderna (NASDAQ:MRNA), which like CureVac's are also based on mRNA technology, have an efficacy of over 85%.

Moderna stock hit a record high this week after tests showed its vaccine was also effective against the delta variant, first identified in India.

The CureVac study involved about 40,000 adult volunteers in Europe and Latin America. Efficacy was 77% in the age group below 60 years of age when considering only moderate to severe symptoms and excluding mild cases.

CureVac said it had sent the data to the European Union drugs regulator. Beyond CVnCoV, the company said it is developing second-generation COVID-19 vaccine candidates in partnership with GlaxoSmithKline (NYSE:GSK).

Related Articles

CureVac Slumps After Confirming COVID Vaccine Candidate Only 48% Effective

Investor Elliott wants GSK leadership settled before split

Krispy Kreme raises $500 million after pricing U.S. IPO below range